TransMedics Group, Inc. (TMDX)
| Market Cap | 4.33B |
| Revenue (ttm) | 566.35M |
| Net Income (ttm) | 91.77M |
| Shares Out | 34.17M |
| EPS (ttm) | 2.54 |
| PE Ratio | 50.00 |
| Forward PE | 49.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 553,314 |
| Open | 127.42 |
| Previous Close | 127.62 |
| Day's Range | 124.87 - 128.81 |
| 52-Week Range | 55.00 - 156.00 |
| Beta | 2.05 |
| Analysts | Buy |
| Price Target | 134.80 (+6.32%) |
| Earnings Date | Oct 29, 2025 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung trans... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price target is $134.8, which is an increase of 6.32% from the latest price.
News
2 Under-the-Radar Stocks That Have Soared This Year
TransMedics Group's revolutionary organ care system is driving its strong results. Abivax is a David among Goliaths, and its growth story might just be getting started.
TransMedics Director Sells 4,142 Shares as Wall Street Maintains Buy Ratings: Is the Stock Still a Buy?
Director Edward Basile executed an exercise of 4,142 options with immediate sale of all resulting shares in TransMedics Group (TMDX +0.07%) on October 29, 2025, as disclosed in the SEC Form 4 filing.
3 Top Stocks to Buy in December
MercadoLibre has tremendous potential in the Latin American e-commerce and fintech markets. TransMedics Group is preparing to expand into Italy and has plenty of room to grow in the U.S. as well.
1 Growth Stock I'm Thankful for -- and the Unstoppable Stock I'm Buying Using the Lessons It Taught Me
As contradictory as it may sound, my most financially painful transaction has been one of my best investing lessons. These lessons apply to many stocks that I hold, but one in particular stands out to...
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
ANDOVER, Mass. , Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
Short interest data offers a look into investor sentiment and potential risk within the stock market and can help investors gauge how much skepticism or confidence the market has in a company's future...
2 Strong Healthcare Stock Picks for Growth Investors
The health industry offers opportunities beyond the big, well-known names. TransMedics Group boasts a sticky business model that is highly profitable.
Polen U.S. Small Cap Growth Q3 2025 Portfolio Performance And Attribution
During the third quarter of 2025, the U.S. Small Cap Growth Composite Portfolio returned 21.4% gross and 21.1% net of fees. Bloom Energy is a provider of solid oxide fuel cells that play a critical ro...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics: Growth Tailwinds Should Provide Upside In 2026
TransMedics delivered solid year-over-year growth in Q3, despite seasonal weakness and concerns over U.S. liver market saturation. The next-gen heart and lung trials, along with an increased focus on ...
TransMedics: Q3 Results Disappointed, As Expected (Rating Upgrade)
TransMedics shares dropped after Q3 results beat consensus but missed high investor expectations, creating a favorable entry point. Q3 is seasonally weak for TMDX, but the current selloff makes valuat...
TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript
TransMedics Group, Inc. ( TMDX) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Confe...
TransMedics Reports Third Quarter 2025 Financial Results
ANDOVER, Mass. , Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025
ANDOVER, Mass. , Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
2 Outstanding Healthcare Stocks to Buy and Hold for a Decade
One great thing about the healthcare sector is that the need for medical services never goes out of style, and in fact, is likely to be in even higher demand in the next decade.
TransMedics: I'm More Bullish Than Ever
TransMedics remains a strong buy despite recent pullback, driven by seasonal weakness and changing transplant transport trends. TMDX's next-gen OCS heart and lung devices, along with kidney perfusion ...
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion techn...
TransMedics: Upcoming Trials Are Critical
Concerns about seasonal weakness have dragged TransMedics' share price lower in recent weeks. While TransMedics' growth is moderating, there remains a sizeable growth opportunity within just the U.S. ...
TransMedics Group, Inc. (TMDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
TransMedics Group, Inc. (NASDAQ:TMDX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:00 AM EDT Company Participants Waleed Hassanein - Founder, President, CEO & Director...
TransMedics: Just Like The CEO, I'm Buying
TransMedics remains a Strong Buy after stellar growth, innovative technology, and founder-led leadership, with shares up 88% YTD, far outpacing the S&P 500. The company's unique OCS platform, integrat...
TransMedics to Present at Upcoming September Investor Conferences
ANDOVER, Mass. , Aug. 25, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics: CEO Is Buying Shares Ahead Of A Potentially Concerning Q3
TransMedics delivered another strong beat-and-raise quarter, but Q3 faces a likely seasonal slowdown that could disappoint optimistic investors. The long-term thesis remains robust: best-in-class pres...
Technical Tuesday: SPX All-Time High, OKLO Bull Flags & TMDX Bullish SMA
@CharlesSchwab's Kevin Horner says technical trends on the SPX indicate a market that "does not want to sell off." He highlights key levels in the index investors should watch.
TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
ANDOVER, Mass. , Aug. 4, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...